ISSUE 1303
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
Continued use of a long-acting beta-2 agonist for treatment of asthma may cause down-regulation of the beta-2 receptor with loss of the bronchoprotective effect from rescue therapy with a short-acting beta-2 agonist. After a large study (SMART) found an increased risk of asthma-related deaths in patients receiving the long-acting beta-2 agonist salmeterol,1 a boxed warning was added to the labeling of all medications containing a long-acting beta-2 agonist. Now the FDA has completed a meta-analysis of 110 asthma treatment studies in 60,954 patients taking any of the long-acting beta-2 agonist formulations listed in the table.
RESULTS OF META-ANALYSIS – Overall, use of a long-acting beta-2 agonist was associated with an increased risk of a composite endpoint of asthmarelated death, intubation or hospitalization; the highest risk was in children 4-11 years old. There was no significant increase in risk
... moreWould you like to read the rest of this issue? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE